Pneumonia nursing: complete reference guide for nursing students

Pneumonia is an acute infection of the lung parenchyma that causes inflammation, fluid accumulation in the alveoli, and impaired gas exchange. It is one of the most common serious infections managed in hospital settings and a leading cause of infection-related death worldwide. Nursing students will encounter pneumonia across every clinical rotation – from the ED to the ICU to long-term care.

This reference covers everything you need: the three pneumonia types and how to classify them, pathophysiology, clinical presentation, diagnostics including CURB-65 scoring, nursing interventions, antibiotic selection by type, complications, patient education, and NCLEX-style practice questions. Use this alongside the ABG interpretation cheat sheet and the nursing lab values cheat sheet – both are essential for managing pneumonia patients.

CAP vs HAP vs VAP: how to classify pneumonia

Classifying pneumonia by acquisition setting is clinically important because it predicts the causative organisms and drives antibiotic selection.

Community-acquired pneumonia (CAP)

CAP is pneumonia that develops outside the hospital or within 48 hours of admission (before hospital flora could colonize the patient). It is the most common type nursing students will encounter in general medical-surgical settings.

Typical organisms:

• Streptococcus pneumoniae – the most common bacterial cause overall
• Haemophilus influenzae – common in patients with COPD or smoking history
• Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila – atypical organisms
• Respiratory viruses (influenza, SARS-CoV-2, RSV) – increasingly recognized as significant causes; influenza is also a leading predisposing factor for secondary bacterial pneumonia

In the CDC EPIC study of 2,259 US adults hospitalized with CAP, a pathogen was found in only 38% despite extensive testing. Viruses (23%) were detected more often than bacteria (11%), and the single most common findings were human rhinovirus (9%), influenza (6%), and S. pneumoniae (5%) (reference 4). Expect most patients to be treated empirically, without a confirmed organism.

Risk factors: Advanced age, smoking, COPD, heart failure, diabetes, immunosuppression, recent viral illness.

Hospital-acquired pneumonia (HAP)

HAP is pneumonia that develops 48 hours or more after hospital admission in a patient who was not incubating the infection at the time of admission. Because hospital environments harbor antibiotic-resistant organisms, HAP carries a significantly higher mortality than CAP.

Typical organisms:

• Staphylococcus aureus (including MRSA)
• Pseudomonas aeruginosa
• Klebsiella pneumoniae and other Gram-negative enteric bacilli
• Acinetobacter baumannii (particularly in ICU settings)

Risk factors: Prolonged hospitalization, recent surgery, immunosuppression, altered consciousness (aspiration risk), prior antibiotic exposure (selects resistant organisms), nasogastric tube use.

Ventilator-associated pneumonia (VAP)

VAP is pneumonia that develops more than 48 hours after endotracheal intubation. The 2016 IDSA/ATS guideline treats it as a separate group from HAP, reserving “HAP” for hospital-onset pneumonia that is not associated with mechanical ventilation. VAP is the most serious of the three types, and bundles of evidence-based nursing practices lower the risk.

Typical organisms: Same spectrum as HAP – Pseudomonas aeruginosa, MRSA, Klebsiella, and other resistant Gram-negative rods.

VAP prevention (nursing role) – essential practices in the 2022 SHEA/IDSA compendium:

• Avoid intubation where safe – high-flow nasal oxygen or noninvasive ventilation as appropriate
• Minimize sedation – sedation protocols or daily spontaneous awakening trials, paired with a ventilator liberation protocol (spontaneous breathing trials)
• Maintain and improve physical conditioning – early exercise and mobility
• Head of bed elevated 30–45°
• Daily oral care with toothbrushing, without chlorhexidine (see note below)
• Early enteral rather than parenteral nutrition
• Change the ventilator circuit only when visibly soiled or malfunctioning

The compendium classes subglottic secretion drainage endotracheal tubes as an additional approach for patients expected to need more than 48–72 hours of ventilation, having reclassified it from an essential practice in the 2022 update. Many unit “ventilator bundles” also include deep vein thrombosis and stress ulcer prophylaxis. Those protect against other ICU complications; the 2022 compendium found stress ulcer prophylaxis has no effect on VAP rates.

Chlorhexidine oral care – an important update. Older VAP bundles, including the IHI ventilator bundle, included daily chlorhexidine oral care, and the 2014 SHEA compendium treated it as an option that may lower VAP rates. The 2022 compendium moved it to “generally not recommended”: the apparent VAP-rate benefit disappeared when analysis was limited to double-blinded trials, and some meta-analyses raised a possible mortality signal. Oral care with toothbrushing is now the essential practice. Many facility bundles still contain chlorhexidine, so follow local policy, and be aware that older NCLEX question banks and textbooks lag current practice here.

Pathophysiology: how pneumonia impairs gas exchange

Pneumonia begins when a pathogen overcomes normal host defenses (mucociliary clearance, cough reflex, alveolar macrophages) and establishes infection in the lung parenchyma.

The inflammatory cascade unfolds in four overlapping stages:

1. Congestion (day 1–2). Bacteria multiply in the alveoli and trigger the inflammatory response. Capillaries dilate (hyperemia), and protein-rich fluid begins to leak into the alveolar spaces.
2. Red hepatization (day 2–4). Massive exudate fills the alveoli. Red blood cells, neutrophils, fibrin, and bacteria pack the alveolar spaces, giving the lung a firm, liver-like consistency. The affected area consolidates – air is displaced by exudate.
3. Gray hepatization (day 4–8). Red cells lyse and are removed. Fibrin and leukocytes dominate. The lobe remains consolidated but turns gray. Gas exchange remains severely impaired.
4. Resolution (day 8+). Macrophages clear debris. Fibrin dissolves. Normal alveolar architecture is restored – in uncomplicated cases.

These classic stages describe untreated lobar pneumococcal pneumonia. Early antibiotics shorten or interrupt the sequence, so the day ranges are approximate.

The key physiological consequence is ventilation-perfusion (V/Q) mismatch. Consolidated lung units receive blood flow (perfusion) but no air (ventilation). Deoxygenated blood returning from these units mixes with oxygenated blood from healthy lung – this intrapulmonary shunt reduces arterial oxygen tension (PaO2). The result is hypoxemia. In severe pneumonia, hypoxemia is profound and hypercapnia develops as CO2 elimination also fails.

Review ABG interpretation to understand the blood gas patterns associated with pneumonia severity: an acute respiratory alkalosis (low PaCO2) is common early as patients hyperventilate to compensate; a rising PaCO2 is a danger sign indicating ventilatory fatigue.

Clinical presentation

Classic (typical) bacterial pneumonia

Classic presentation is associated with typical organisms such as Streptococcus pneumoniae:

• Acute onset – fever, chills, rigors developing over hours
• Productive cough – purulent sputum; rusty or blood-tinged sputum is classic for S. pneumoniae
• Pleuritic chest pain – sharp, localized, worse with inspiration or coughing (suggests pleural involvement)
• Tachycardia and tachypnea
• Decreased breath sounds and dullness to percussion over the affected lobe
• Bronchial breath sounds and egophony over consolidated areas

Atypical (walking) pneumonia

Atypical presentation is associated with Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella, and viruses:

• Gradual onset – prodrome of malaise, headache, and low-grade fever over days
• Non-productive or minimally productive cough – often the dominant symptom
• No or minimal pleuritic chest pain
• Relatively well-appearing patient – symptoms may seem disproportionately mild for the radiographic findings (“walking pneumonia”)
• Extrapulmonary features – myalgias, arthralgias, diarrhea, mental status changes (particularly with Legionella)

Key distinction for NCLEX: Beta-lactam antibiotics (penicillins, cephalosporins) work by attacking the bacterial cell wall, and they do not cover atypical organisms. Mycoplasma has no cell wall at all, while Legionella and Chlamydophila live inside host cells, where beta-lactams do not reach them. Atypical coverage requires macrolides (azithromycin), tetracyclines (doxycycline), or fluoroquinolones (levofloxacin).

Diagnostics

Chest X-ray

CXR is the standard initial diagnostic for suspected pneumonia. Key findings:

• Lobar consolidation – homogeneous opacification of one or more lobes, often with an air bronchogram (air-filled bronchi visible against the opaque lung background). Classic for bacterial (typical) pneumonia.
• Patchy or bilateral infiltrates – more common with atypical pneumonia or viral pneumonia.
• Interstitial pattern – bilateral ground-glass or reticular opacities suggest viral or Mycoplasma pneumonia, or COVID-19.
• Pleural effusion – fluid blunting the costophrenic angle. Can indicate parapneumonic effusion or developing empyema.

Laboratory values

Review lab values for reference ranges. Expected findings in pneumonia:

• CBC: Elevated WBC (leukocytosis) with a left shift (increased bands/immature neutrophils). WBC may be normal or low in atypical pneumonia or in immunocompromised patients.
• CRP and procalcitonin: Elevated. Procalcitonin is more specific for bacterial infection than CRP, and is used to support antibiotic de-escalation and duration decisions. One caveat the 2019 ATS/IDSA guideline makes explicit: procalcitonin is not accurate enough to justify withholding antibiotics in a patient with radiographically confirmed CAP. A low value never overrides the clinical picture.
• ABG: Hypoxemia (low PaO2), initially with respiratory alkalosis (low PaCO2 from hyperventilation). Rising PaCO2 indicates respiratory failure.
• Blood cultures: Two sets from separate sites, drawn before antibiotics. The 2019 ATS/IDSA guideline recommends them for hospitalized patients with severe CAP or with risk factors for MRSA or Pseudomonas, and not routinely for nonsevere CAP. Yield is low: about 2% in outpatients and 9% in inpatients with nonsevere CAP.
• Sputum Gram stain and culture: Ideally collected before antibiotics. Quality specimen requires > 25 PMNs and < 10 squamous epithelial cells per low-power field.
• Urinary antigen tests: Rapid, highly specific tests for Legionella pneumophila serogroup 1 and Streptococcus pneumoniae. Useful because they remain positive even after antibiotic initiation.
• Pulse oximetry: Continuous monitoring for hospitalized patients. The British Thoracic Society target range is 94–98% for most acutely ill adults, or 88–92% for patients at risk of hypercapnic respiratory failure such as those with COPD. SpO2 below target despite oxygen calls for urgent escalation.

CURB-65 severity scoring

CURB-65 is a validated clinical decision tool that predicts 30-day mortality in CAP and guides the admit vs. outpatient decision. Each criterion scores one point:

A note on PSI vs CURB-65. The 2019 ATS/IDSA CAP guideline recommends the Pneumonia Severity Index (PSI) over CURB-65 for the admission decision, because PSI identifies a larger share of patients as low risk, has higher discriminative power for mortality, and has trial evidence that it safely increases outpatient treatment. PSI has a known weakness: it can underestimate illness severity in younger patients, so it is used alongside clinical judgment. CURB-65 remains widely taught and widely used at the bedside – it is far faster to calculate (five variables versus the PSI’s twenty) and it is what most NCLEX questions test. Learn CURB-65 for the exam, and expect to see PSI in guideline-driven practice.

The figures for scores 0–1, 3 and 4–5 come from the Lim 2003 derivation cohort (reference 3), which reported 30-day mortality of 0.7%, 3.2%, 17%, 41.5% and 57% for scores 0, 1, 3, 4 and 5. The score 2 figure is the pooled rate across both study cohorts, where scores 0–1 carried 1.5% mortality, score 2 carried 9.2% and scores 3–5 carried 22%.

Nursing application: While CURB-65 is a physician/NP tool for admission decisions, nurses use it for risk stratification and to prioritize monitoring. A patient with a CURB-65 score of 3 or higher needs frequent vital sign assessment, continuous pulse oximetry, early lactate if sepsis is suspected, and preparation for potential rapid deterioration. Monitor for confusion (new onset), rising respiratory rate, and hemodynamic instability – these are the clinical correlates of the CURB-65 criteria.

Nursing interventions

Positioning and oxygenation

• Head of bed 30–45° – this is the single most important pneumonia positioning intervention. It reduces aspiration risk, improves diaphragmatic excursion, and promotes drainage of secretions. In VAP patients this is mandatory.
• Supplemental oxygen to a target of SpO2 94–98%, or 88–92% for patients at risk of hypercapnia (or per provider order). Delivery method escalates with severity: nasal cannula → simple face mask → non-rebreather mask → high-flow nasal cannula (Optiflow) → BiPAP → intubation.
• “Good lung down” in unilateral pneumonia (where tolerated) – lie the patient on the unaffected side, which puts the consolidated lung uppermost. Gravity directs the larger share of pulmonary blood flow to the dependent lung; when that dependent lung is the healthy, well-ventilated one, V/Q matching improves and PaO2 rises. The same principle explains positioning in unilateral pleural effusion. Two exceptions override it: with hemoptysis, lung abscess, or empyema, keep the affected side down so infected material or blood does not spill into the healthy lung.

Respiratory therapy and airway clearance

• Incentive spirometry – encourage use every 1–2 hours while awake. Sustained maximal inspiration opens collapsed alveoli and prevents atelectasis. Set achievable goals and track progress.
• Deep breathing and coughing exercises – splint the chest with a pillow before coughing to reduce pain and encourage effective effort.
• Nebulized bronchodilators (albuterol, ipratropium) when bronchospasm is present or in patients with underlying COPD. See the COPD nursing reference for bronchodilator sequencing.
• Chest physiotherapy and postural drainage – particularly for patients with copious secretions or underlying bronchiectasis.
• Oral suctioning for patients unable to clear secretions independently.

Fluid and temperature management

• IV fluids for dehydrated patients or those unable to tolerate oral intake. Adequate hydration thins secretions and supports cardiac output. Monitor fluid balance carefully in patients with concurrent heart failure or renal insufficiency.
• Antipyretics (acetaminophen, ibuprofen) for fever management. High fever increases metabolic demand and oxygen consumption. Monitor temperature trends – a declining fever generally indicates treatment response; persistent or rising fever suggests treatment failure, complications, or resistant organisms.
• Electrolyte replacement as needed. Check lab values for sodium, potassium, and magnesium – all are commonly abnormal in severely ill patients.

Infection control

• Standard precautions for all pneumonia patients.
• Droplet precautions for influenza and other respiratory virus pneumonias (surgical mask, generally put on when entering the room).
• Contact precautions for MRSA pneumonia (gown and gloves). MRSA is not airborne – airborne precautions with an N95 are reserved for tuberculosis, measles, and varicella.
• Transmission-based precautions for Legionella are not required (no person-to-person spread), but standard precautions apply.

Monitoring for deterioration

Every shift, assess for signs of clinical deterioration and early sepsis. Pneumonia is the leading infectious cause of sepsis – review the sepsis nursing reference for SIRS criteria, qSOFA score, and sepsis bundle management. Early warning signs include: rising heart rate and respiratory rate, falling SpO2, new hypotension, new confusion or agitation, and rising lactate.

Medications: antibiotic selection by pneumonia type

Antibiotic selection is driven by pneumonia type (CAP vs HAP/VAP), severity, and local resistance patterns. Nurses do not prescribe antibiotics but must understand the treatment rationale, administer them on time, and monitor for adverse effects.

Key nursing considerations for antibiotics:

• Administer the first dose promptly. When pneumonia presents with possible septic shock or probable sepsis, the Surviving Sepsis Campaign 2026 guideline calls for antimicrobials ideally within 1 hour of recognition; for possible sepsis without shock, within 3 hours if concern for infection persists after rapid assessment.
• Monitor for allergic reactions, particularly with penicillin-class agents. Ask about allergy history before the first dose.
• Vancomycin is nephrotoxic. Maintenance doses are adjusted to renal function, and the 2020 ASHP/IDSA/PIDS/SIDP consensus guideline replaced trough-only monitoring with AUC-guided dosing (target AUC 400–600) for serious MRSA infections. Review lab values for renal function ranges.
• Fluoroquinolones (levofloxacin, moxifloxacin) carry a boxed warning for tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and worsening of myasthenia gravis. They can also prolong the QT interval – monitor the ECG in patients with baseline QT prolongation or on other QT-prolonging drugs.
• Azithromycin also prolongs QT – same precaution applies.
• De-escalate antibiotics once culture results return – this is an antimicrobial stewardship priority.
• Treatment courses are short. The 2019 ATS/IDSA guideline recommends treating CAP until the patient is clinically stable and for no less than 5 days in total (7 days for MRSA or Pseudomonas), and the 2016 IDSA/ATS guideline recommends 7 days for most HAP and VAP.

Complications to monitor

Pneumonia can progress rapidly. Nursing vigilance for these complications changes outcomes:

Pleural effusion. Fluid accumulates in the pleural space as a parapneumonic response. Small effusions are common and often resolve with treatment. A large effusion causes progressive dyspnea and decreased breath sounds at the base. Confirm with CXR or ultrasound.

Empyema. A parapneumonic effusion becomes infected, filling the pleural space with pus. Signs include persistent fever despite antibiotics, pleuritic chest pain, and failure to improve. Requires drainage (thoracentesis or chest tube) in addition to antibiotics.

Lung abscess. Parenchymal necrosis creates a pus-filled cavity. Associated with aspiration, anaerobic organisms, or alcoholism. CXR shows a cavitary lesion with an air-fluid level. Treatment requires prolonged antibiotics (weeks to months).

Respiratory failure. Progressive V/Q mismatch and hypoxemia leading to ventilatory failure. Monitor for rising respiratory rate, falling SpO2, accessory muscle use, diaphoresis, and confusion. Prepare for escalating oxygen support and potential intubation. Severe bilateral pneumonia can present as ARDS.

Sepsis and septic shock. Pneumonia is the most common infectious cause of sepsis. Monitor for signs of infection with organ dysfunction: fever or hypothermia, tachycardia, tachypnea, altered mental status, rising lactate, and hypotension. Activate the sepsis pathway promptly. Review sepsis nursing care for full bundle management. Use vital signs by age to identify tachycardia and tachypnea thresholds.

Patient education

Patient education reduces reinfection risk, promotes recovery, and improves vaccination rates.

Vaccination. Two vaccines are central to pneumonia prevention:

• Pneumococcal vaccine – ACIP lowered the routine age threshold from 65 to 50 in October 2024. A single dose of PCV15, PCV20, or PCV21 is now recommended for all adults aged ≥ 50 who are conjugate-vaccine-naive or whose history is unknown, and for younger adults (19–49) with high-risk conditions. If PCV15 is the dose given, follow with PPSV23 one year later (a minimum of 8 weeks for adults with an immunocompromising condition, a cochlear implant, or a cerebrospinal fluid leak); PCV20 and PCV21 complete the series on their own. Note that older study guides still list 65 as the threshold – check the vaccine year on any resource you study from.
• Influenza vaccine – annual; influenza frequently precedes secondary bacterial pneumonia.
• Teach patients that vaccines do not prevent all types of pneumonia but significantly reduce risk of severe disease and hospitalization.

Taking antibiotics as prescribed. Teach patients to take every dose for the number of days the prescriber ordered, even once they feel better, and never to save leftover tablets or share them. Current CAP courses are short (often 5 days), and the prescriber sets the stopping point based on clinical stability. Patients should call if fever, breathlessness, or cough worsens instead of stopping or extending the course on their own.

Smoking cessation. Smoking impairs mucociliary clearance and alveolar macrophage function – two key defenses against pneumonia. Every clinical encounter is an opportunity to discuss cessation. Refer patients to resources: nicotine replacement therapy, varenicline, behavioral counseling, and state quit lines.

Activity and recovery. Pneumonia resolves slowly. Radiographic changes often lag clinical improvement by weeks. Teach patients to gradually increase activity, rest when fatigued, and follow up as directed. Recurrent symptoms (returning fever, worsening cough, dyspnea) require prompt evaluation.

Aspiration precautions (for at-risk patients). Aspiration is a risk factor for CAP and HAP. Teach patients and caregivers: sit upright during meals, avoid eating when drowsy, use proper dentures, and maintain good oral hygiene. Patients with dysphagia require a formal swallowing evaluation.

NCLEX-style practice questions

Question 1

A nurse is caring for a patient admitted with community-acquired pneumonia. The patient’s vital signs are: temp 38.9°C, HR 108, RR 28, BP 88/56 mmHg, SpO2 88% on 2 L/min nasal cannula. The patient is confused. What is the nurse’s priority action?

A. Increase the nasal cannula flow rate to 6 L/min B. Notify the provider immediately and prepare for potential ICU transfer C. Collect a sputum specimen for culture D. Administer the scheduled antipyretic

Correct answer: B

Rationale: This patient already scores at least 2 on CURB-65 from the bedside data alone: new confusion (1 point) and SBP < 90 mmHg (1 point). The respiratory rate of 28 does not meet the ≥ 30 threshold, and age and BUN are not given, so the full score could be 2 to 4. New confusion plus hypotension alongside hypoxemia (SpO2 88% on oxygen) represents clinical deterioration and possible septic shock, requiring immediate provider notification and potential ICU-level care. While increasing oxygen delivery and antipyretics are appropriate interventions, the priority is recognizing that this patient is critically ill and escalating care. Sputum collection is important but is not the priority over hemodynamic instability.

Question 2

A nurse is teaching a patient about pneumococcal vaccination. The patient, who is 67 years old, states, “I already got the flu shot – do I still need this one?” Which response by the nurse is most accurate?

A. “The flu shot protects against all respiratory infections, so you are covered.” B. “The pneumococcal vaccine protects against bacterial pneumonia caused by Streptococcus pneumoniae, which is different from influenza.” C. “You only need the pneumococcal vaccine if you smoke or have chronic lung disease.” D. “The pneumococcal vaccine is only for children under five years old.”

Correct answer: B

Rationale: The influenza vaccine and pneumococcal vaccine target different pathogens. Influenza vaccine prevents viral illness caused by influenza strains. Pneumococcal vaccine prevents disease caused by Streptococcus pneumoniae, the leading bacterial cause of CAP. Both are recommended for this patient – annual influenza vaccine for all adults, and pneumococcal conjugate vaccine for all adults aged ≥ 50. The two vaccines are frequently administered together and are complementary – influenza can predispose patients to secondary bacterial pneumonia, making both vaccines important.

Question 3

A patient is intubated and mechanically ventilated for respiratory failure secondary to severe pneumonia. To prevent ventilator-associated pneumonia, which nursing action is the highest priority?

A. Administer prophylactic antibiotics every 12 hours B. Maintain the head of bed at 30–45° continuously C. Turn the patient every 4 hours D. Change the ventilator circuit every 24 hours

Correct answer: B

Rationale: Elevating the head of bed 30–45° is an essential practice in the 2022 SHEA/IDSA VAP prevention compendium and the only evidence-based VAP measure among these options. It reduces aspiration of oropharyngeal and gastric secretions into the lower airways, the main route by which VAP develops. Prophylactic antibiotics are not standard practice for VAP prevention and contribute to resistance. Repositioning is important for pressure injury prevention but is not a VAP-specific intervention. Ventilator circuits should be changed only when visibly soiled or malfunctioning – routine changes have not been shown to reduce VAP and may increase risk.

Question 4

A nurse is reviewing ABG results for a patient with pneumonia: pH 7.49, PaCO2 30 mmHg, PaO2 62 mmHg, HCO3 23 mEq/L. Which interpretation is correct?

A. Compensated metabolic alkalosis B. Uncompensated respiratory alkalosis C. Compensated respiratory acidosis D. Mixed respiratory and metabolic acidosis

Correct answer: B

Rationale: pH is elevated (alkalosis). PaCO2 is low (respiratory cause – the patient is hyperventilating, driving CO2 down). HCO3 is normal, indicating no renal compensation has occurred yet. This is uncompensated respiratory alkalosis, which is the expected early ABG pattern in pneumonia – the hypoxemia (PaO2 62 mmHg) drives the patient to hyperventilate, lowering PaCO2 and raising pH. A rising PaCO2 toward normal or above would indicate ventilatory fatigue and impending respiratory failure. Review the ABG interpretation cheat sheet for the full interpretation framework.

Question 5

A hospitalized patient with HAP is ordered vancomycin IV. Before administering the first dose, which nursing action is most important?

A. Check the patient’s most recent BUN and creatinine B. Administer the dose over 15 minutes to reduce adverse effects C. Confirm the patient has no penicillin allergy D. Ensure the patient has eaten within the last 2 hours

Correct answer: A

Rationale: Vancomycin is nephrotoxic, and maintenance dosing depends on renal function. A baseline BUN and creatinine establishes the starting point for dosing and for monitoring kidney injury during therapy; report an elevated or rising creatinine to the provider or pharmacist. Vancomycin should be infused over at least 60 minutes and at no more than 10 mg/min (not over 15 minutes) to prevent a vancomycin infusion reaction (formerly called “red man syndrome”) – flushing, pruritus, and hypotension from histamine release. Vancomycin is not a penicillin; cross-reactivity is not a clinical concern. Food intake is irrelevant for IV medications.

Question 6

A nurse assesses a patient who was admitted two days ago for left lower lobe pneumonia. The patient now reports sharp left-sided chest pain that worsens with deep breathing, and breath sounds are absent at the left base. The patient’s temperature is 38.6°C despite 48 hours of antibiotics. Which complication should the nurse suspect?

A. Pulmonary embolism B. Empyema C. Pneumothorax D. Lung abscess

Correct answer: B

Rationale: The clinical picture – persistent fever despite antibiotics, pleuritic chest pain, and absent breath sounds at the base – is classic for a parapneumonic effusion that has become infected (empyema). The absence of breath sounds at the base indicates fluid accumulation. Empyema requires drainage in addition to antibiotics. Pulmonary embolism would present with sudden pleuritic chest pain and hypoxemia but not typically with localized absence of breath sounds at the base in the context of ongoing pneumonia. Pneumothorax presents with sudden onset, absent breath sounds, tracheal deviation, and hemodynamic compromise. Lung abscess develops more gradually and produces a cavitary lesion, not a pleural effusion.

Related references

Build your respiratory reference library with these complementary guides:

• Sepsis nursing reference – pneumonia is the leading cause of sepsis. This guide covers SIRS criteria, qSOFA, Sepsis-3 definitions, and the hour-1 bundle.
• ABG interpretation cheat sheet – essential for interpreting the respiratory alkalosis of early pneumonia and the acidosis of respiratory failure.
• COPD nursing reference – COPD is a major risk factor for pneumonia and complicates management. Covers oxygen therapy, bronchodilators, and GOLD staging.
• Nursing lab values cheat sheet – WBC, procalcitonin, BUN, creatinine, and ABG normal ranges for pneumonia assessment.
• Tuberculosis nursing reference – TB can present as a subacute pneumonia-like illness; covers airborne precautions, RIPE therapy, and upper-lobe infiltrate pattern.
• Vital signs by age – baseline respiratory rate and heart rate ranges for recognizing tachypnea and tachycardia in pneumonia patients across age groups.
• RSV nursing reference – RSV is a leading cause of viral pneumonia in infants and a significant cause of lower respiratory tract disease in elderly adults. Covers bronchiolitis management, HFNC, nirsevimab prophylaxis, and isolation precautions.

References

1. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
2. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases. 2016;63(5):e61–e111. doi:10.1093/cid/ciw353
3. Lim WS, van der Eerden MM, Laing R, et al. Defining Community Acquired Pneumonia Severity on Presentation to Hospital: An International Derivation and Validation Study. Thorax. 2003;58(5):377–382. doi:10.1136/thorax.58.5.377
4. Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New England Journal of Medicine. 2015;373(5):415–427. doi:10.1056/NEJMoa1500245
5. Wunderink RG, Waterer GW. Community-Acquired Pneumonia. New England Journal of Medicine. 2014;370(6):543–551. doi:10.1056/NEJMcp1214869
6. Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. Nature Reviews Disease Primers. 2021;7(1):25. doi:10.1038/s41572-021-00259-0
7. Klompas M, Branson R, Cawcutt K, et al. Strategies to Prevent Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia in Acute-Care Hospitals: 2022 Update. Infection Control and Hospital Epidemiology. 2022;43(6):687–713. doi:10.1017/ice.2022.88
8. Chalmers JD, Singanayagam A, Akram AR, et al. Severity Assessment Tools for Predicting Mortality in Hospitalised Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Thorax. 2010;65(10):878–883. doi:10.1136/thx.2009.133280
9. File TM Jr, Marrie TJ. Burden of Community-Acquired Pneumonia in North American Adults. Postgraduate Medicine. 2010;122(2):130–141. doi:10.3810/pgm.2010.03.2130
10. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to Initiate or Discontinue Antibiotics in Acute Respiratory Tract Infections. Cochrane Database of Systematic Reviews. 2017;(10):CD007498. doi:10.1002/14651858.CD007498.pub3 (replaces the 2012 edition of this review, doi:10.1002/14651858.CD007498.pub2)
11. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morbidity and Mortality Weekly Report. 2025;74(1):1–8. doi:10.15585/mmwr.mm7401a1
12. Centers for Disease Control and Prevention. Pneumococcal Vaccine Recommendations (clinical guidance for healthcare providers). Atlanta, GA: CDC; updated February 25, 2026; accessed October 8, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
13. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine. 2005;171(4):388–416. doi:10.1164/rccm.200405-644ST (superseded by reference 2; the HCAP category it introduced has since been retired)
14. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases. 2007;44(Suppl 2):S27–S72. doi:10.1086/511159 (superseded by reference 1; retained for historical context)
15. Klompas M, Branson R, Eichenwald EC, et al. Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2014;35(8):915–936. doi:10.1086/677144 (superseded by reference 7; this edition treated chlorhexidine oral care as an option that may lower VAP rates, and the 2022 update moved it to “generally not recommended”)
16. Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Critical Care Medicine. 2026;54(4):725–812. doi:10.1097/CCM.0000000000007075
17. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036
18. O’Driscoll BR, Howard LS, Earis J, et al. BTS Guideline for Oxygen Use in Adults in Healthcare and Emergency Settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729
19. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Atlanta, GA: CDC; 2007 (web edition updated November 2023). https://www.cdc.gov/infection-control/hcp/isolation-precautions/index.html
20. US National Library of Medicine. DailyMed: Vancomycin Hydrochloride for Injection (prescribing information, Mylan Institutional, published August 28, 2026) and Levofloxacin Tablets (prescribing information, boxed warning). Accessed October 8, 2026. https://dailymed.nlm.nih.gov/